Aerpio Pharmaceuticals has completed patient enrollment in its phase 2b TIME-2b study of AKB-9778, its treatment candidate for moderate to severe nonproliferative diabetic retinopathy, according to a press release.
The double-masked, placebo-controlled, multicenter trial enrolled 167 patients who will receive 48 weeks of treatment with AKB-9778 15 mg subcutaneously once a day, AKB-9778
15 mg subcutaneously twice a day or placebo subcutaneously twice a day. The trial’s primary endpoint is the percentage of patients who improve by two or more steps in diabetic retinopathy severity score in
Uncategorized